Recent Updates
Recently added Catalysts
TNDM Negative Sentiment

Tandem Diabetes Care, Inc. (TNDM) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Key Takeaway: Tandem Diabetes Care, Inc. is under investigation for potential violations of federal securities laws following a malfunction in its insulin pumps. On August 7, 2025, the company announced that this malfunction could trigger discontinuation of insulin delivery, posing health risks to users. As a result, the stock price plummeted by nearly 20%, affecting shareholders. The Law Offices of Howard G. Smith are reaching out to investors who may have incurred losses as a result.
Price reaction · baseline $12.14 (2025-09-30 close) · hit after-hours · clean, no other TNDM news in the window
day 0 close · peak
+2.2%

Market Sentiment Analysis

CONCERNS & RISKS

  • Tandem Diabetes Care disclosed a malfunction in insulin pumps that could disrupt insulin delivery.
  • This malfunction may lead to serious health issues requiring hospitalization.
  • The company's stock price dropped by 19.9% following the news, harming investor interests.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~39 mo
Minimal dilution risk
Lead asset
tozadenant
Phase 1 · N/A, as Healthy Volunteers

Full Press Release Details

BENSALEM, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TANDEM DIABETES CARE, INC. (TNDM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
On August 7, 2025, Tandem disclosed that a malfunction had been identified in some of its insulin pumps which could “trigger an error resulting in a discontinuation of insulin delivery” which “could result in hyperglycemia due to discontinuation of insulin delivery” and “may require hospitalization or intervention from a medical professional.” The Company stated that it had sent notices to impacted customers between July 22 and 24, 2025.
On this news, Tandem’s stock price fell $2.87, or 19.9%, to close at $11.52 per share on August 7, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you purchased Tandem securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Law Offices of Howard G. Smith
Howard G. Smith, Esquire

Frequently Asked Questions

What is Tandem Diabetes Care being investigated for?

Tandem Diabetes Care is under investigation for potential violations of federal securities laws.

What issue was disclosed by Tandem on August 7, 2025?

Tandem revealed a malfunction in some insulin pumps that could halt insulin delivery.

How did Tandem's stock react to the August 7 disclosure?

The stock price dropped by $2.87, or 19.9%, closing at $11.52 per share.

How can investors contact Howard G. Smith's law office?

Investors can reach Howard G. Smith by phone at (215) 638-4847 or via email.

What risks are associated with the insulin pump malfunction?

The malfunction may lead to hyperglycemia and could require medical intervention.

Last updated: Oct 1, 2025